Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy

Inclusion Criteria:

* Histologically proven anal squamous cell carcinoma (SCC) (WHO 2004), including anal canal carcinoma (UICC 2002) and anal margin carcinoma (UICC 2002)
* All stages except T1 N0 M0 after local excision (UICC 2002)
* Age ≥ 18 years
* ECOG Status 0-1
* Patients that have understand protocol and signed informed consent form
* Sufficient bone marrow function: WBC ≥ 3,0 x 10\^9/l, Platelets ≥ 100 x 10\^9/l, Hemoglobin ≥ 10 g/dl
* Sufficient liver function: Bilirubin \< 1,5 mg/dl, SGOT, SGPT, alkaline phosphatase, gGT less than 3 times upper limit of normal

Exclusion Criteria:

* Stage T1 N0 M0 after local excision (UICC 2002)
* Uncontrolled, severe cardiac dysfunction (NYHA III/IV)
* Pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy
* Myocardial infarction within the past 12 months
* Congestive heart failure
* Complete bundle branch block
* New York Heart Association (NYHA) class III or IV heart disease
* Chronic inflammatory disease of the intestine
* Active intractable or uncontrolled infection
* Chronic diarrhea ( \> NCI CTC-Grad 1)
* Acute thrombosis
* Collagen vascular disease
* Cardiac pacemaker
* HIV-infection; Patients with hepatitis A or B virus infection, with HPV infection or Patients receiving immune suppressive treatment can be included
* Devices that preclude deep regional hyperthermia (Endoprosthesis, stent in vascular system, acute thrombosis)
* Any metal implants (with exception of non-clustered marker clips)
* Conditions that preclude the application of fractionated pelvic radiotherapy
* Conditions that preclude regular follow-up
* Pregnant or breast feeding women
* Prior pelvic radiotherapy
* Prior chemotherapy
* Drug addiction
* On-treatment participation on other trials
* Prior or concurrent malignancy or leucemia (≤ 5 years prior to enrolment in study) except anal cancer or non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1 if the patient is continuously disease-free
* The presence of increased radiation sensitivity, for example ataxia teleangiectatica, or similar
* Psychological, familial, sociological, or geographical condition that would preclude study compliance